Project Grant R01CA307561
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $405K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $501,803 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to decode the stromal niches of antigen-presenting cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. The research aims to elucidate interactions between antigen-presenting cancer-associated fibroblasts (APCAFs) and other cell types within specialized stromal niches in pancreatic tumors. The work will examine...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $166,000 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct research on targeting cell death pathways to prevent KRAS inhibitor resistance in pancreatic ductal adenocarcinoma. The recipient will investigate how combining pan-KRAS inhibitors with novel TRAIL-based therapeutic approaches—specifically a chimeric Fc-TRAIL fusion protein with enhanced stability and natural...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $376,886 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop new inhibitors of Site-One Protease (S1P) for prevention and treatment of cancers. The funded research targets lipid production as a cancer vulnerability. Increased lipogenesis is a hallmark of multiple cancer types, including clear cell renal cell carcinoma and hepatocellular carcinoma. Sterol regulatory...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $621,632 on June 17, 2026, under the Cancer Treatment Research program (CFDA 93.395) to elucidate the molecular and metabolic mechanisms underlying disulfidptosis and therapeutically target this form of regulated cell death in SLC7A11-high cancers. The research employs human cancer cell lines and integrated cell-based molecular analyses including metabolomics, proteomics, CRISPR screening, and biochemical...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded The University of Texas Southwestern Medical Center $639,514 on June 1, 2026, for mechanistic characterization of NVL inhibition by benzothiazepinones as a non-genotoxic chemotherapy strategy under the Cancer Biology Research program (CFDA 93.396). The award funds research to define the catalytic mechanism of NVL, an essential AAA+ ATPase required for large ribosomal subunit...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $402,011 to The University of Texas Southwestern Medical Center on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how the KEAP1-NRF2 redox-sensing pathway regulates CD8 T-cell adaptation to persistent antigen receptor signaling in cancer and chronic infection contexts. The funded research addresses T-cell exhaustion, a dysfunctional...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $621,121 on July 10, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate tumor-niche co-evolution mechanisms driving ovarian cancer metastasis and therapeutic resistance. The research integrates clonal barcoding, single-cell RNA sequencing, and in vivo CRISPR screens to trace the evolutionary trajectory of metastatic ovarian cancer cells and define niche adaptive changes that...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $687,594 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and characterize preclinical models of small cell lung cancer brain metastasis and evaluate therapeutic response. The recipient is conducting research to establish spontaneous brain metastasis models in patient-derived xenografts (PDXs) of small cell lung cancer. The work addresses a critical gap in SCLC research:...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $614,260 on May 11, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how hypoxia regulates ferroptosis, a form of iron-dependent cell death implicated in cancer suppression. The research examines the oxygen-sensing mechanisms through which hypoxia inhibits ferroptosis independently of the canonical prolyl hydroxylase-von Hippel-Lindau-hypoxia inducible factor pathway, with...